



Medicinal products in ATC-group C02, Antihypertensives

Reading instructions for the table below

Approved indication: The specified indication(s) of an active substance and pharmaceutical form, if stated, relate(s) to the medicinal product that has been licensed for the longest period of time.

Reimbursement status: The current reimbursement status of the medicinal product.

Treatment price per day: The listed prices per day are based on the medicinal products' reimbursement prices calculated in accordance with the Danish Medicines Agency's guidelines for evaluation and comparison of medicinal products in reassessments of reimbursement status dated 4 July 2006, cf. Appendices C1 and D.

Consumption: The number of persons in treatment is based on the Danish Medicines Agency's Register of Medicinal Product Statistics, cf. www.medstat.dk.

Single substance products for oral use

C02AB01	Methyldopa
Pharmaceutical forms	Tablets
Traded names	Aldomet
Approved indication	Arterial hypertension
Dispensing terms	B
Reimbursement status	General reimbursement
Price per day	Tablets 1000 mg: DKK 3.76
Consumption	1,058 persons in treatment in 2006 1.061 persons in treatment in the first 10 months of 2007
Discussion	The substance is exclusively used in combination with other antihypertensives and in particular in hypertension treatment during pregnancy (90% is used for women, median age 35 years). The consumption is very modest and stationary over the years despite the apparent increase in the past two years.
Assessment	The Committee assesses that there are <u>no</u> grounds to open a case to change the reimbursement status for oral medicinal products in ATC group C02AB01

C02AC05	Moxonidine
Pharmaceutical forms	Tablets
Traded names	Physiotens, Moxonidin "Actavis", Moxonidin "Ratiopharm"
Approved indication	Arterial hypertension
Dispensing terms	B
Reimbursement status	General reimbursement
Price per day	Tablets 0.3 mg: DKK 2.48
Consumption	6,942 persons in treatment in 2006. 6,975 persons in treatment in the first 10 months of 2007
Discussion	The substance is used in combination with other antihypertensive drugs and exclusively as supplementary treatment when other treatment has proved insufficient. The consumption is modest, but has seen a steady increase over the years, and the substance now has its place in the treatment of hypertension.
Assessment	The Committee assesses that there are <u>no</u> grounds to open a case to change the reimbursement status for oral medicinal products in ATC group C02AC05

Price survey of C02 - Antihypertensives

Appendix C1
29 January 2008

Average lowest unit price for 6 price periods (period start from 22 october to 31 december 2007)

1. ATC	2. Medicinal product	3. Reimbursement status/dispensing terms	4. DDD (mg)	5. Daily Dose (mg) ¹	6. Pharmaceutical form	7. Strength (mg)	8. Average lowest unit price (DKK)	9. Price per day (DKK)	
C02AB	Methyldopa								
C02AB01	Methyldopa (levorotatory)	•	B	1000	1000 ^{2 3}	Film-coated tablets	250	0.94	3.76
C02AC	Imidazoline receptor agonists								
C02AC05	Moxonidine	•	B	0.3	0.3 ^{2 4}	Film-coated tablets	0.2 / 0.4	1.65 / 1.76	2.48

Notes and explanations:

1	Can be given once a day unless otherwise noted
2	DDD (Defined Daily Dose) by the WHO
3	Divided into 2-4 daily doses
4	Can be divided into 2 daily doses

Symbols and abbreviations

Reimbursement status	
-	Not eligible for general reimbursement
●	General reimbursement for prescription-only medicinal products
■	Limited general reimbursement for over-the-counter medicinal products.
⊗	Limited general reimbursement for prescription-only medicinal products

Dispensing terms	
A	Only to be dispensed once on the same prescription, unless dispensed in smaller doses at a time.
AP4	Subject to the provisions of section 4 of the Executive Order on prescriptions.
AP4BG	Only to be dispensed to hospitals. Subject to the provisions of section 4 of the Executive Order on prescriptions.
AP4NB	Only to be dispensed to hospitals or following prescription by specific medical specialists. Subject to the provisions of section 4 of the Executive Order on prescriptions.
B	Only to be dispensed once on the same prescription, unless stated otherwise.
BEGR	Only to be dispensed to hospitals. Same terms apply as for dispensing group A.
HA	Over-the-counter drugs. Pharmacy-restricted medicinal product.
HF	Over-the-counter drugs. Non-pharmacy-restricted human medicinal product.
HX	Over-the-counter drugs. Non-pharmacy-restricted human medicinal product. Maximum 1 package/customer/day.
NBS	Only to be dispensed to hospitals or following prescription by specific medical specialists. Same terms apply as for dispensing group A.